🇺🇸 FDA
Pipeline program

IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., Rixathon 500 mg concentrate for solution for infusion, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, Rixathon 100 mg concentrate for solution for infusion, MTX HEXAL 2,5 mg Tabletten, -, Methotrexat-GRY® 50 mg/2 ml Injektionslösung, ASFOTASE ALFA

AA-HPP-407

Approved small_molecule active

Quick answer

IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., Rixathon 500 mg concentrate for solution for infusion, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, Rixathon 100 mg concentrate for solution for infusion, MTX HEXAL 2,5 mg Tabletten, -, Methotrexat-GRY® 50 mg/2 ml Injektionslösung, ASFOTASE ALFA for HYPOPHOSPHATASIA is a Approved program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).

Program details

Company
Alexion Europe SAS
Indication
HYPOPHOSPHATASIA
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials